Controlling Health Care Costs CMS Set to Negotiate with Pharmaceutical Manufacturers on Drug Prices Blog / Sep 08, 2023
Improving Health Care Quality How Value-Based Payment Can Improve Drug Spending, Utilization, and Equity Blog / Jul 12, 2023
Controlling Health Care Costs Bipartisan Congressional Support for PBM Reform Grows Blog / Jun 21, 2023
Controlling Health Care Costs States Take on Affordability — Hospital and Pharmaceutical Spending Are Pressing Priorities, but Difficult to Tackle Blog / Jan 26, 2023
Controlling Health Care Costs CMS Announces Public Comment and Engagement Opportunities in Medicare Drug Negotiation Process Blog / Jan 20, 2023
Controlling Health Care Costs Making Prescription Drugs Affordable: Options for the Center for Medicare and Medicaid Innovation Blog / Nov 10, 2022
Controlling Health Care Costs How Should Medicare Negotiate Drug Prices? A Summary of the Options Explainer / Oct 27, 2022
Controlling Health Care Costs Can State Prescription Drug Affordability Boards Address High-Cost Drug Prices? Blog / Oct 11, 2022
Controlling Health Care Costs The Federal 340B Drug Pricing Program: What It Is, and Why It’s Facing Legal Challenges Explainer / Sep 08, 2022
Controlling Health Care Costs The Impact of Pharmaceutical Wholesalers on U.S. Drug Spending Issue Briefs / Jul 20, 2022
Controlling Health Care Costs The Accelerated Approval Pathway for New Drug Therapies: Controversies and Proposed Fixes Explainer / Jul 14, 2022